ArticleProceedings of the National Academy of Sciences of the United States of America2014
Clearance of pathological antibodies using biomimetic nanoparticles.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 283 citations in OpenAlex.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- PLL-g-HPA Hydrogel Microneedles Loaded With Rhoifolin Target Macrophages to Alleviate Fibroblast Senescence for Diabetic Wound Healing.Advanced healthcare materials · 2026Article
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- Lysosome self-sorting nanodegraders for hepatic clearance of pathogenic serum mediators.Nature nanotechnology · 2026Article
- Engineered Cell Membrane-Coated Nanoparticles: A New Strategy for Pancreatic Cancer Therapy.ACS pharmacology & translational science · 2026Review
- PSMA-Targeting Macrophage Membrane-Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer.Exploration (Beijing, China) · 2026Article
- Bioinspired and Biomimetic Nanocarriers: Advances in Exosomes and Cell-Membrane-Coated Systems for Therapeutic Applications.International journal of nanomedicine · 2026Review
- Cell Membrane-Coated Nanoparticles: Advanced Drug Delivery Systems for Chronic Wound Healing Therapy.International journal of nanomedicine · 2026Review
- Revolutionizing healthcare with nanosensor technology.RSC advances · 2025Review
- Cancer Cell Membrane-Coated NPs as a Biomimetic Strategy for Precision Tumor Therapy.Pharmaceutics · 2025Review
- Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.Materials today. Bio · 2025Review
- Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier.Journal of nanobiotechnology · 2025Review
- Immunoengineered mitochondria for efficient therapy of acute organ injuries via modulation of inflammation and cell repair.Science advances · 2025Article
- Natural, Engineered, and Hybrid Platelet Membrane-Based Nanotherapeutics for Inflammatory Diseases.International journal of nanomedicine · 2025Review
- Review
- Enzyme-armed nanocleaner provides superior detoxification against organophosphorus compounds via a dual-action mechanism.Journal of nanobiotechnology · 2024Article
- Adipose-Derived Stem-Cell-Membrane-Coated PLGA-PEI Nanoparticles Promote Wound Healing via Efficient Delivery of miR-21.Pharmaceutics · 2024Article
- Red Blood Cell Membrane-Coated Nanoparticles Enable Incompatible Blood Transfusions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Pathological antibodies have been demonstrated to play a key role in type II immune hypersensitivity reactions, resulting in the destruction of healthy tissues and leading to considerable morbidity for the patient. Unfortunately, current treatments present significant iatrogenic risk while still falling short for many patients in achieving clinical remission. In the present work, we explored the capability of target cell membrane-coated nanoparticles to abrogate the effect of pathological antibodies in an effort to minimize disease burden, without the need for drug-based immune suppression. Inspired by antibody-driven pathology, we used intact RBC membranes stabilized by biodegradable polymeric nanoparticle cores to serve as an alternative target for pathological antibodies in an antibody-induced anemia disease model. Through both in vitro and in vivo studies, we demonstrated efficacy of RBC membrane-cloaked nanoparticles to bind and neutralize anti-RBC polyclonal IgG effectively, and thus preserve circulating RBCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.